Helius Medical Technologies, Inc. (NASDAQ:HSDT) Short Interest Down 5.5% in November

Helius Medical Technologies, Inc. (NASDAQ:HSDT) saw a large decline in short interest in November. As of November 30th, there was short interest totalling 89,800 shares, a decline of 5.5% from the November 15th total of 95,000 shares. Based on an average trading volume of 361,500 shares, the short-interest ratio is currently 0.2 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Helius Medical Technologies stock. Armistice Capital LLC bought a new stake in Helius Medical Technologies, Inc. (NASDAQ:HSDT) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 130,000 shares of the company’s stock, valued at approximately $127,000. Armistice Capital LLC owned about 4.39% of Helius Medical Technologies as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 18.63% of the company’s stock.

Helius Medical Technologies Stock Performance

HSDT opened at $0.47 on Wednesday. The business’s 50-day simple moving average is $0.52 and its 200-day simple moving average is $0.73. The company has a market cap of $1.75 million, a P/E ratio of -0.08 and a beta of 1.68. Helius Medical Technologies has a one year low of $0.37 and a one year high of $9.50.

Analysts Set New Price Targets

Separately, Maxim Group restated a “hold” rating on shares of Helius Medical Technologies in a report on Wednesday, October 16th.

Helius Medical Technologies Company Profile

Helius Medical Technologies, Inc, a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise.